| name | endo-rtcgm-vs-no-cgm-t2d-insulin-su |
| description | Suggests real-time CGM over no CGM for outpatients with type 2 diabetes who use insulin and/or sulfonylureas and are at high risk for hypoglycemia to detect and prevent low glucose events. Consider when initiating CGM in T2D patients on insulin/SU with a history of severe hypoglycemia or impaired awareness of hypoglycemia (IAH). |
Real-Time Continuous Glucose Monitoring vs No CGM for Outpatients with Type 2 Diabetes on Insulin/Sulfonylurea at High Hypoglycemia Risk
STEP 1 — Gather Information
Confirm outpatient status, type 2 diabetes diagnosis, current use of insulin and/or sulfonylurea (SU), and assess hypoglycemia risk: history of severe hypoglycemia requiring assistance, impaired awareness of hypoglycemia (IAH), renal or hepatic dysfunction, age ≥65 years, or other predisposing conditions. Collect medication list, recent hypoglycemia episodes, comorbidities, and patient awareness of low glucose symptoms.
STEP 2 — Rule In / Rule Out
Is the patient at high risk for hypoglycemia (e.g., severe hypoglycemia needing help, IAH, renal/hepatic insufficiency)?
- Yes → Proceed to Step 3.
- No → Do not initiate CGM based on this recommendation; consider other indications or routine SMBG.
STEP 3 — Classify or Stratify
Is the patient currently prescribed insulin and/or sulfonylurea (SU)?
- Yes → Proceed to Step 4.
- No → This recommendation does not apply; reassess hypoglycemia management strategies.
STEP 4 — Decide
For outpatients with T2D on insulin and/or SU who are at high hypoglycemia risk, suggest initiating real-time CGM rather than no CGM. Provide device education, set hypoglycemia alerts, and instruct periodic point-of-care blood glucose (POC-BG) checks to validate CGM readings, especially during sensor warm-up or symptomatic discrepancies.
Clinical Guardrails / Mimics / Pitfalls
Do not rely on CGM alone for treatment decisions without confirmatory fingerstick validation when symptoms do not match sensor readings, during warm‑up, or in extremes of glycemia. Avoid CGM in patients with skin infection, hypoperfusion, vasoconstriction, or those unable to perform periodic SMBG. Recognize alarm fatigue and ensure patient education on device troubleshooting; CGM does not replace SMBG for calibration or confirmation. Consider cost, insurance coverage, and access barriers before prescribing.
Concrete Clinical Example
A 68‑year‑old woman with T2D on basal insulin and glimepiride (SU) reports two episodes of severe hypoglycemia requiring assistance in the past month and has impaired awareness of hypoglycemia. She is otherwise healthy and an outpatient. Initiate real‑time CGM, provide training on sensor insertion and alert response, and advise twice‑daily fingerstick checks to validate CGM values, especially if she feels low but sensor reads normal.
Source: Management of Individuals With Diabetes at High Risk for Hypoglycemia: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2023, https://doi.org/10.1210/clinem/dgac596
